Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
As shown in Table 3, severe plaque progression (≥3 new plaques) was linked to increased age, body mass index, systolic blood pressure, pulse pressure, glucose, potassium and 25-hydroxy (25-OH) vitamin D levels.
Source: RESULTS. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Patients were followed for 48 months for CVE.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Matrix Gla protein polymorphism rs1800802 is associated with atheroma plaque progression and with cardiovascular events in a chronic kidney disease cohort
Study design awaiting verification · Clinical Kidney Journal · 2024
Original publication title
Matrix Gla protein polymorphism rs1800802 is associated with atheroma plaque progression and with cardiovascular events in a chronic kidney disease cohort
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Chronic kidney disease (CKD) is associated with increased atherosclerotic burden and higher risk for cardiovascular events (CVE). Atherosclerosis has a significant genetic component and, in CKD, it is influenced by mineral metabolism alterations. Therefore, genetic modifications of mineral metabolism: related proteins could affect atherosclerosis in CKD patients. In the present study we investigated the role of single nucleotide polymorphisms (SNPs) of the matrix gamma-carboxy glutamic acid protein (MGP) on atherosclerosis progression and CVE in a CKD cohort.
Source: BackgroundAbstract: What methods does the paper describe?
A total of 2187 CKD patients from the Observatorio Nacional de Aterosclerosis en Nefrologia (NEFRONA) study were genotyped for SNPs present in the matrix gamma-carboxy glutamic acid (Gla) protein (MGP) gene. Atheromatosis was detected by vascular ultrasound. Progression of atheromatosis, defined as an increase in territories with plaque, was assessed after 24 months. Patients were followed for 48 months for CVE. Association of SNPs with plaque progression was assessed by logistic regression and their capacity to predict CVE by Cox regression.
Source: MethodsAbstract: Results
Three SNPs of the MGP gene were analyzed. No association of the rs4236 or the rs1800801 SNPs was detected with any of the outcomes. However, patients homozygotes for the minor allele of the rs1800802 SNP showed higher adjusted risk for plaque progression [odds ratio 2.3 (95% confidence interval 1.06 to 4.9)] and higher risk of suffering a CVE [hazard ratio 2.16 (95% confidence interval 1.13 to 4.12)] compared with the rest of genotypes. No association of the SNP with total or dp-ucMGP levels was found in a subsample.
Source: ResultsAbstract: Conclusions
The rs1800802 polymorphism of MGP is associated with plaque progression and CVE in CKD patients.
Source: ConclusionsAuthors’ abstract
ABSTRACT
Background
Chronic kidney disease (CKD) is associated with increased atherosclerotic burden and higher risk for cardiovascular events (CVE). Atherosclerosis has a significant genetic component and, in CKD, it is influenced by mineral metabolism alterations. Therefore, genetic modifications of mineral metabolism: related proteins could affect atherosclerosis in CKD patients. In the present study we investigated the role of single nucleotide polymorphisms (SNPs) of the matrix gamma-carboxy glutamic acid protein (MGP) on atherosclerosis progression and CVE in a CKD cohort.
Methods
A total of 2187 CKD patients from the Observatorio Nacional de Aterosclerosis en Nefrologia (NEFRONA) study were genotyped for SNPs present in the matrix gamma-carboxy glutamic acid (Gla) protein (MGP) gene. Atheromatosis was detected by vascular ultrasound. Progression of atheromatosis, defined as an increase in territories with plaque, was assessed after 24 months. Patients were followed for 48 months for CVE. Association of SNPs with plaque progression was assessed by logistic regression and their capacity to predict CVE by Cox regression.
Results
Three SNPs of the MGP gene were analyzed. No association of the rs4236 or the rs1800801 SNPs was detected with any of the outcomes. However, patients homozygotes for the minor allele of the rs1800802 SNP showed higher adjusted risk for plaque progression [odds ratio 2.3 (95% confidence interval 1.06 to 4.9)] and higher risk of suffering a CVE [hazard ratio 2.16 (95% confidence interval 1.13 to 4.12)] compared with the rest of genotypes. No association of the SNP with total or dp-ucMGP levels was found in a subsample.
Conclusions
The rs1800802 polymorphism of MGP is associated with plaque progression and CVE in CKD patients.
Publication and source details
Original title: Matrix Gla protein polymorphism rs1800802 is associated with atheroma plaque progression and with cardiovascular events in a chronic kidney disease cohort
Serafí Cambray; Marcelino Bermúdez-López; Alicia Garcia-Carrasco; Jose M Valdivielso; NEFRONA investigators Aladrén RegidorMª JoséAlmirallJaumePonzEstherColomaJesús ArteagaRubioBajoAladrén RegidorMª JoséRodríguezBelartGascónAntonioSanjuanJordi BoverArteroJosep BronsomsCabezuelo RomeroJuan BCasesMurayCalviño VarelaJesúsAcevedoPilar CaroBassaJordi CarrerasAmenósAleix CasesJiménezElisabet MassóLópezRosario MorenoGuldrisSecundino CigarránPrietoSaray LópezMongayLourdes ComasComermaIsabelCompte JovéMª TeresaIzquierdoMarta Cuberesde ÁlvaroFernandoHevia OjangurenCovadongade Arriba de la FuenteGabrieldel Pino y PinoMª DoloresDiaz-Tejeiro IzquierdoRafaelDotoriMartaDuarteVerónicaEstupiñan TorresSaraFernández ReyesMª JoséFernández RodríguezMª LoretoFernándezGuillerminaGalán SerranoAntonioGarcía CantónCesarGarcía HerreraAntonio LGarcía MenaMercedesGil SacalugaLuisGórrizJosé LuisHuarte LozaEmmaLermaJosé LuisLiebana CañadaAntonioMarín ÁlvarezJesús PedroMartín AlemanyNàdiaMartín GarcíaJesúsMartínez CastelaoAlbertoMartínez VillaescusaMaríaMartínezIsabelMoina EgurenIñigoMoreno Los HuertosSilviaMouzo MircoRicardoMunar VilaAntoniaMuñoz DíazAna BeatrizNavarro GonzálezJuan FNietoJavierCarreñoAgustínNovoa FernándezEnriqueOrtizAlbertoParaísoVicentePérez FontánMiguelPeris DomingoAnaPiñera HacesCelestinoPrados GarridoMª DoloresPrieto VelascoMarioPuig MaríCarminaRivera GorrínMaiteRubioEstherRuizPilarSalgueira LazoMercedesMartínez PuertoAna IsabelSánchez TomeroJosé AntonioSánchezJosé EmilioLormanRamon SansSarachoRamonSarriasMariaSerónDanielSolerMaría JoséBarriosClaraSousaFernandoToranDanielMolinaFernando TorneroCarrascoJosé Javier UsónCortesIldefonso ValeraVilaprinyo del PerugiaMª MerceVirto RuizRafael CGilGil Área Básica Sanitaria de AránInésToroJose Mª FernándezIbáñezJuan Antonio Divisón Garrote Centro de Salud de Casas
Clinical Kidney Journal · 2024
Correspondence to: Jose M. Valdivielso; E-mail: valdivielso@irblleida.catCorrespondence to: Serafí Cambray; E-mail: serafi.cambray@medicina.udl.catThese authors contributed equally to this work.
The NEFRONA investigators are listed in the Appendix.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T15:45:56.391234+00:00
DOI: 10.1093/ckj/sfad257 · PMC10768782